非小细胞肺癌患者表皮生长因子受体基因突变危险因素分析

Analysis about Risk Factors of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-small Cell Lung Cancer

目的:探讨非小细胞肺癌患者表皮生长因子受体基因突变的危险因素。方法:选取2019年1月~2020年3月收治的111例非小细胞肺癌患者作为研究对象,根据表皮生长因子受体突变结果将其分为突变组(76例)与非突变组(35例)。采用单因素分析法、多因素Logistic回归分析法对研究对象的临床资料及相关指标进行分析。结果:突变组与非突变组性别、年龄、病理组织学分类、M分期、吸烟史相比较,差异有统计学意义(P<0.05);T分期、N分期、并发脑转移、并发骨转移、并发其他脏器转移、ECOG PS评分、血清癌胚抗原、细胞角蛋白19片段抗原21-1、糖链抗原15-3、鳞状细胞癌抗原相比较,差异无统计学意义(P>0.05)。多因素Logistic回归分析显示,女性、腺癌、M1期、无吸烟史是非小细胞肺癌患者表皮生长因子受体突变的独立危险因素(P<0.05),年龄是非小细胞肺癌患者表皮生长因子受体突变的非独立相关因素(P>0.05)。结论:临床应加强女性、腺癌、M1期、无吸烟史非小细胞肺癌患者的表皮生长因子受体突变检测,并根据检测结果指导治疗。

Objective:To analyze the risk factors of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.Methods:From January 2019 to March 2020,111 patients of non-small cell lung cancer were selected as the study objects.According to the mutation results of epidermal growth factor receptor,they were divided into mutation group with 76 cases and non-mutation group with 35 cases.The single-factor analysis and multi-factor Logistic regression analysis were used to analyze the clinical data and related indicators of all study objects.Results:There were significant differences in gender,age,histopathological classification,M stage and smoking history between mutation group and non-mutation group(P<0.05),while no significant differences were found in T stage,N stage,brain metastasis,bone metastasis,other organ metastasis,ECOG PS scores and serum carcinoembryonic antigen,cytokeratin 19 fragment antigen 21-1,carbohydrate antigen 15-3 and squamous cell carcinoma antigen between these two groups(P>0.05).The multi-factor Logistic regression analysis showed that,women,adenocarcinoma,M1 stage and no-smoking history were independent risk factors for epidermal growth factor receptor mutation in non-small cell lung cancer patients(P<0.05),while age was a independent factor(P>0.05).Conclusion:We should strengthen the detection of epidermal growth factor receptor mutation in female,adenocarcinoma,M1 stage and no-smoking history non-small cell lung cancer patients,then guide the treatment according to the epidermal growth factor receptor mutation results.